Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia

Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia

IntroductionOlder patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effect...

Full description

Saved in:
Bibliographic Details
Main Authors: Qingyang Liu, Jingjing Yang, Lei Lv, Xiawei Zhang, Meng Li, Lingmin Xu, Sai Huang, Yu Jing, Liping Dou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
venetoclax
azacitidine
CACAG-VEN regimen
older patients
acute myeloid leukemia
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525110/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items